Faculty Publications
Infectious Diseases
Jan 11, 2007

D.M. Gaughan, M.D. Hughes, J.M. Oleske, K. Malee, S. Nachman, for the PACTG 219C Team.  Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics 2004;113(6):e544-e551.

J. Hitti, L.M. Frenkel, A.M. Stek, S.A. Nachman, D. Baker, A. Gonzalez-Garcia, A. Provisor, E.M. Thorpe, M.E. Paul, M. Foca, J. Gandia, S. Huang, L.J. Wei, L.M. Stevens, D.H. Watts, J. McNamara, for the PACTG 1022 Study Team.  Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36(3):772-776.

C.V. Fletcher, R. Yogev, S.A. Nachman, A. Wiznia, S. Pelton, K. McIntosh, and K. Stanley.  Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection. Pharmacotherapy 2004;24(4):453-9.

R.J. Jeremy, S. Kim, M. Nozyce, S. Nachman, K. McIntosh, S.I. Pelton, R. Yogev, A. Wiznia, G.M. Johnson, P. Krogstad, and K. Stanley for the Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams.  Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics 2005;115(2):380-387.

S. Nachman,  P. Gona, W. Dankner, A. Weinberg, R. Yogev, A. Gershon, M. Rathore, J. S. Read, S. Huang, C. Elgie, K. Hudgens, and W. Hughes.  The Rate of Serious Bacterial Infections Among HIV-Infected Children with Immune Reconstitution Who Have Discontinued Opportunistic Infection Prophylaxis. Pediatrics 2005;115:488-494.

S.A. Nachman, J.C. Lindsey, J. Moye, K.E. Stanley, G.M. Johnson, P.A. Krogstad, and A.A. Wiznia for the PACTG 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. J Pediatr Infect Dis 2005;24(4):352-357.

S.I. Pelton, K. Stanley, R. Yogev, C.V. Fletcher, K. McIntosh, A. Wiznia, and S. Nachman for the PACTG 338 Study Team.  Switch from ritonavir to indinavir combination therapy for HIV-infected children. Clin Infect Dis 2005;40:1181-7.

H.M. Rosenblatt, K.E. Stanley, L.Y.Song, G.M. Johnson, A.A. Wiznia, S.A. Nachman, P.A. Krogstad and the PACTG 377 Study Team. Immunologic response to combination therapy in children with clinically stable HIV infection. J Infect Dis 2005;192:445-455.

S.K. Gupta, J.A. Eustace, J.A. Winston, I.I. Boydstun, T.S. Ahuja, R.A. Rodriguez, K.T. Tashima, M. Roland, N. Franceschini, F.J. Palella, Jr., J.L. Lennox, P.E. Klotman, S.A. Nachman, S.D. Hall, L.A. Szczech. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medical Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40(11):1559-85.

J.Y. Ang, S. Ray-Mazumder, S.A. Nachman, C. Rongkavilt, B.I. Asmar and C.L. Ren. Use of complementary and alternative medicine by parents of pediatric HIV, pediatric asthma and well child patients. South Med J 2005; 98(9):869-75.

L.J. Grando, D.C. Machado, S. Spitzer, S. Nachman, F. Ferguson, B. Berentsen, L.S. Yurgel. Viral coinfection in the oral cavity of HIV-infected children: relation among HIV viral load, CD4+ T lymphocyte count and detection of EBV, CMV and HSV.  Pesquisa Odontologica Brasileira (Brazilian Oral Research) 2005;19(3):228-34.

H.M. Rosenblatt, L.Y. Song, S.A. Nachman, K.E. Stanley, P.A. Krogstad, G.M. Johnson, A.A. Wiznia and the PACTG 377 Study Team. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005;116(3):698-703.

J.R. King, S. Nachman, R. Yogev, J. Hodge, G. Aldrovandi, M.D. Hughes, J. Chen, A. Wiznia, B. Damle, E.P. Acosta. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in HIV-infected children – PACTG 403. Pediatr Infect Dis J 2005; 24(10):880-885.

H.M. Rosenblatt, L.Y. Song, S.A. Nachman, K.E. Stanley, P.A. Krogstad, G.M. Johnson, and A.A. Wiznia. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immun 2005; 116(3):698-703.

L. Gabis, A. Belman, W. Huang, M. Milazzo, and S. Nachman. Clinical and imaging study of HIV-1 infected youth on HAART therapy – A pilot study using MR spectroscopy. Accepted J Child Neurol, July 2005.

P Gona, R.B. Van Dyke, P.L. Williams, W.M. Dankner, M.M. Chernoff, S.A. Nachman, G.R. Seage III.  Incidence of opportunistic and other infections in HIV-infected children in the HAART-era.  Accepted Archives of Pediatrics and Adolescent Medicine Dec 2005.

M.L. Nozyce, S.S. Lee, A. Wiznia, S. Nachman, L. Mofenson, E. Smith, R. Yogev, K. McIntosh, K. Stanley, S. Pelton. A behavioral and cognitive profile of clinically stable HIV infected children receiving antiretroviral therapy. Pediatrics 2006 Mar;117(3):763-70.

Weinberg, P. Gona, S.A. Nachman, P. Defechereux, R. Yogev, W. Hughes, D. Wara, C. Elgie, M. Cooper, W. Dankner and the PACTG 1008 Team. Antibody responses to hepatitis A vaccine among HIV-infected children with evidence of immunologic reconstitution on antiretroviral therapy. J Infect Dis Jan 2006;193(2):302-11.

Englund J, Raskino C, Vavro C, Palumbo P, Ross L, McKinney R, Nikolic-Djokic D, Colgrove R, Baker C. Mutations linked to drug resistance, HIV biological phenotype, and their association with disease progression in HIV-infected children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J. 2004;23(1):15-22.

McCloskey, TW, Haridas, V, Pontrelli, L, and Pahwa, S.  Response to Superantigen Stimulation in Peripheral Blood Mononuclear Cells from Children Perinatally Infected with Human Immunodeficiency Virus and Receiving Highly Active Antiretroviral Therapy.  Clin.Diagn.Lab.Immunol. 2004, 11 (5): 957-962.